Follicular Thyroid Cancer Therapeutics Pipeline Market H1 2015 Review Report Available at RnRMarketResearch.com

Share Article

RnRMarketResearch.com adds “Follicular Thyroid Cancer – Pipeline Review, H1 2015” report to its store. The report provides an overview of the follicular thyroid cancer’s therapeutic pipeline.

Follicular Thyroid Cancer Therapeutics Pipeline

Follicular Thyroid Cancer Therapeutics Pipeline

The report “Follicular Thyroid Cancer – Pipeline Review, H1 2015″ provides comprehensive information on the therapeutic development for Follicular Thyroid Cancer. Peripheral Neuropathy (Sensory Neuropathy) is a damage to one or more of peripheral nerves that includes motor, sensory and autonomic fibers. The cause of peripheral neuropathy is often unidentified. The most widespread causes of peripheral neuropathy are diabetes, shingles, kidney failure, various drugs and vitamin shortage. When the peripheral sensory nerves are damaged, they fail to send sensory messages (pain, heat, touch, cold etc). Neuropathy occurs in 60% to 70% of people with diabetes. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report is available at http://www.rnrmarketresearch.com/follicular-thyroid-cancer-pipeline-review-h1-2015-market-report.html.

The report also reviews key players involved in the therapeutic development for Follicular Thyroid Cancer and special features on late-stage and discontinued projects. Companies discussed in this Follicular Thyroid Cancer – Pipeline Review, H1 2015 report include AstraZeneca PLC, Exelixis, Inc., GlaxoSmithKline plc, Novartis AG, Pfizer Inc.

The most universal signs and symptoms of thyroid cancer includes a lump, thyroid nodule, trouble swallowing, throat or neck pain, swollen lymph nodes in the neck, cough and vocal changes. It is not possible to prevent most cases of thyroid cancer. Drug profiles discussed in this report includes cabozantinib s-malate, dabrafenib mesylate, everolimus, sunitinib malate, tetraiodothyroacetic acid nanoparticle, vandetanib. Order a Purchase copy of this report at http://www.rnrmarketresearch.com/contacts/purchase?rname=269533. (This is a premium report priced at US$2000 for a single user License.)

Featured News & Press Releases cover by this “Follicular Thyroid Cancer – Pipeline Review, H1 2015” report include: Oct 31, 2005: FDA Grants ZD6474 (Zactima) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer

Table of contents

List of Tables
Number of Products under Development for Follicular Thyroid Cancer, H1 2015
Number of Products under Development for Follicular Thyroid Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Number of Products under Investigation by Universities/Institutes, H1 2015
Comparative Analysis by Late Stage Development, H1 2015
Comparative Analysis by Clinical Stage Development, H1 2015
Comparative Analysis by Early Stage Development, H1 2015
Products under Development by Companies, H1 2015
Products under Investigation by Universities/Institutes, H1 2015
Follicular Thyroid Cancer - Pipeline by AstraZeneca PLC, H1 2015
Follicular Thyroid Cancer - Pipeline by Exelixis, Inc., H1 2015
Follicular Thyroid Cancer - Pipeline by GlaxoSmithKline plc, H1 2015
Follicular Thyroid Cancer - Pipeline by Novartis AG, H1 2015
Follicular Thyroid Cancer - Pipeline by Pfizer Inc., H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Stage and Target, H1 2015
Number of Products by Stage and Mechanism of Action, H1 2015
Number of Products by Stage and Route of Administration, H1 2015
Number of Products by Stage and Molecule Type, H1 2015
Follicular Thyroid Cancer Therapeutics - Recent Pipeline Updates, H1 2015
Follicular Thyroid Cancer - Dormant Projects, H1 2015

List of Figures
Number of Products under Development for Follicular Thyroid Cancer, H1 2015
Number of Products under Development for Follicular Thyroid Cancer - Comparative Analysis, H1 2015
Number of Products under Development by Companies, H1 2015
Assessment by Monotherapy Products, H1 2015
Number of Products by Top 10 Targets, H1 2015
Number of Products by Stage and Top 10 Targets, H1 2015
Number of Products by Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015
Number of Products by Stage and Top 10 Routes of Administration, H1 2015
Number of Products by Stage and Top 10 Molecule Types, H1 2015

Explore more reports on Central Nervous System (CNS) therapeutics Market at http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics/central-nervous-system-cns-therapeutics.

About Us:
RnRMarketResearch.com is a database of selected syndicated market reports for global and China industries including but not limited to life sciences, information technology & telecommunications, consumer goods, food and beverages, energy and power, automotive and transportation, manufacturing and construction, materials and chemicals, public sector as well as business and financial services. We provide 24/7 online and offline support to our customers.

Share article on socal media or email:

View article via:

Pdf Print

Contact Author

Ritesh Tiwari
@chinamrreport
Follow >
Market Reports China
Like >
Follow us on
Visit website